Advances in the Pharmaceutical Industry

571 Words Feb 24th, 2018 2 Pages
While most companies use the mentality of screening drugs that show the most binding affinity or particularity of drug applicants to a single defined target, this is not always the best way of doing things. Many off target activities or multi-targeted particularities have been successful in targeted therapeutics. For example, Imatinib marketed by Novartis and Sorafenib co-developed and co-marketed by Bayer and Onyx Pharmaceuticals and Nexavar have shown that looking at the broader spectrum of biological context of how a specific agent works is very important. Increasing importance of translational and clinical research in the early stages of drug development can help connect the drug’s activity to biological impact and clinical significance. Improvement in early stage R&D productivity can be increased greatly by looking more at the scientific disease state being treated rather than just looking at the target. Evolving clinical and commercial requirements of the scientific data from the disease state will rapidly advance the early stage patients being tested to clinical trials. A biomarker is a measured indicator of a targeted disease. It can be used in drug development and contributes to increased probability for phase transitioning specifically in phases II & III, the longest phases. A recent study in oncology drug development displayed “908 oncology drug candidates Phase I, II, and III…
Open Document